Date: Wednesday , Sep 23, 2020
Time: 7:00 PM – 8:00 PM EDT
The intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration and diabetic retinopathy.
Visual outcomes in patients with neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) have been greatly enhanced through the integration of anti–vascular endothelial growth factor (VEGF) therapies into treatment protocols. In DR, early intervention with anti-VEGF therapies has demonstrated significant slowing of disease progression and a reduction in vision threatening complications. In those patients with nAMD, significant visual acuity gains have been demonstrated, yet treatment burden often leads to reduced patient adherence, resulting in suboptimal outcomes. Dosing strategies aimed at extending the time between dosing intervals while maintaining early visual acuity gains are evolving. In this educational activity, experts in the field will summarize newer anti-VEGF injection protocols that may improve the long-term management of DR and nAMD, as well as examine real-world clinical data that report on patient-related and anatomical factors that influence outcomes in patients being treated for nAMD and DR.
W. Lloyd Clark, MD
Palmetto Retina Center, LLC
Assistant Clinical Professor of Ophthalmology
University of South Carolina School of Medicine
Michael S. Ip, MD
Professor of Ophthalmology
Medical Director, Doheny Image Reading Center
Doheny Eye Institute
University of California – Los Angeles
For more information on the webinar visit the website: http://www.vindicocme.com/